A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
I5F-MC-JSCC - ClinicalTrials.gov - NCT02718911
The main purpose of this study is to evaluate the safety of the colony-stimulating factor 1 receptor (CSF-1R) inhibitor LY3022855 in combination with durvalumab or tremelimumab in participants with advanced solid tumors.
Trial Summary
Age Range
≥18 yearsConditions the trial is for
Solid TumorsWhat the trial is testing?
Durvalumab, LY3022855, TremelimumabCould I receive a Placebo?
NoEnrollment Goal
72Trial Dates
Jun 16, 2016 - Dec 14, 2018How long will I be in the trial?
The duration of your participation depends on how well your disease responds to the study treatment.Trial Phase
ILilly Trial Alerts
Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.
You will complete the questionnaire on another website.YesNo